Aurinia Pharmaceuticals
AUPH
65 hedge funds and large institutions have $142M invested in Aurinia Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 20 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 17
1.88% less ownership
Funds ownership: 30.11% → 28.23% (-1.9%)
8% less funds holding
Funds holding: 71 → 65 (-6)
19% less capital invested
Capital invested by funds: $176M → $142M (-$33.9M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
46% less call options, than puts
Call options by funds: $3.04M | Put options by funds: $5.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$7.97M |
| 2 |
Goldman Sachs
New York
|
+$3.57M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.78M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.36M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.51M |
| 3 |
Two Sigma Investments
New York
|
-$4.03M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.94M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.94M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
76
Quantbot Technologies
New York
| – | -$275K | -37,554 | Closed |
|
77
TD Asset Management
Toronto,
Ontario, Canada
| – | -$241K | -32,887 | Closed |
|
|
TSS
78
Two Sigma Securities
New York
| – | -$240K | -32,652 | Closed |
|
79
LPL Financial
San Diego,
California
| – | -$209K | -30,002 | Closed |
|
|
AFM
80
Anson Funds Management
Dallas,
Texas
| – | -$250K | -29,900 | Closed |
|
81
Jane Street
New York
| – | -$155K | -21,113 | Closed |
|
|
BFM
82
Boothbay Fund Management
New York
| – | -$129K | -17,614 | Closed |
|
|
PAM
83
Princeton Alpha Management
Princeton Junction,
New Jersey
| – | -$95K | -12,900 | Closed |
|
|
IA
84
IFP Advisors
Tampa,
Florida
| – | -$7K | -1,000 | Closed |
|
|
FMA
85
FNY Managed Accounts
New York
| – | -$5K | -750 | Closed |
|
AUPH Hedge Fund Activity: Q2 2017 in Review
65 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2017, worth a combined $142M — down 19% from $176M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AUPH and 15 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 23 added.
The largest buyer was Polar Capital, opening a new position worth an estimated $7.97M. The largest seller was Great Point Partners, exiting entirely with an estimated $7.34M sold.
- 65 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2017, down from 71 in Q1 2017.
- Funds reported $142M of Aurinia Pharmaceuticals stock for Q2 2017, down 19% quarter-over-quarter.
- 15 funds opened new Aurinia Pharmaceuticals positions in Q2 2017 and 20 closed out, a net change of -5 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2017 was Polar Capital, an estimated $7.97M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2017 was Great Point Partners, an estimated $7.34M sold.
Based on aggregated 13F filings for Q2 2017.